• Je něco špatně v tomto záznamu ?

Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression

P. Holý, V. Hlaváč, K. Šeborová, S. Šůsová, T. Tesařová, L. Rob, M. Hruda, J. Bouda, A. Bartáková, M. Mrhalová, K. Kopečková, M. Al Obeed Allah, J. Špaček, I. Sedláková, P. Souček, R. Václavíková

. 2024 ; 155 (1) : 104-116. [pub] 20240306

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013412

Grantová podpora
NU20-09-00174 Czech Health Research Council

High-grade serous ovarian carcinoma (HGSC) is the most common subtype of ovarian cancer and is among the most fatal gynecological malignancies worldwide, due to late diagnosis at advanced stages and frequent therapy resistance. In 47 HGSC patients, we assessed somatic and germline genetic variability of a custom panel of 144 known or suspected HGSC-related genes by high-coverage targeted DNA sequencing to identify the genetic determinants associated with resistance to platinum-based therapy. In the germline, the most mutated genes were DNAH14 (17%), RAD51B (17%), CFTR (13%), BRCA1 (11%), and RAD51 (11%). Somatically, the most mutated gene was TP53 (98%), followed by CSMD1/2/3 (19/19/36%), and CFTR (23%). Results were compared with those from whole exome sequencing of a similar set of 35 HGSC patients. Somatic variants in TP53 were also validated using GENIE data of 1287 HGSC samples. Our approach showed increased prevalence of high impact somatic and germline mutations, especially those affecting splice sites of TP53, compared to validation datasets. Furthermore, nonsense TP53 somatic mutations were negatively associated with patient survival. Elevated TP53 transcript levels were associated with platinum resistance and presence of TP53 missense mutations, while decreased TP53 levels were found in tumors carrying mutations with predicted high impact, which was confirmed in The Cancer Genome Atlas data (n = 260). Targeted DNA sequencing of TP53 combined with transcript quantification may contribute to the concept of precision oncology of HGSC. Future studies should explore targeting the p53 pathway based on specific mutation types and co-analyze the expression and mutational profiles of other key cancer genes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013412
003      
CZ-PrNML
005      
20240905133421.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.34908 $2 doi
035    __
$a (PubMed)38447012
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Holý, Petr $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000269505563
245    10
$a Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression / $c P. Holý, V. Hlaváč, K. Šeborová, S. Šůsová, T. Tesařová, L. Rob, M. Hruda, J. Bouda, A. Bartáková, M. Mrhalová, K. Kopečková, M. Al Obeed Allah, J. Špaček, I. Sedláková, P. Souček, R. Václavíková
520    9_
$a High-grade serous ovarian carcinoma (HGSC) is the most common subtype of ovarian cancer and is among the most fatal gynecological malignancies worldwide, due to late diagnosis at advanced stages and frequent therapy resistance. In 47 HGSC patients, we assessed somatic and germline genetic variability of a custom panel of 144 known or suspected HGSC-related genes by high-coverage targeted DNA sequencing to identify the genetic determinants associated with resistance to platinum-based therapy. In the germline, the most mutated genes were DNAH14 (17%), RAD51B (17%), CFTR (13%), BRCA1 (11%), and RAD51 (11%). Somatically, the most mutated gene was TP53 (98%), followed by CSMD1/2/3 (19/19/36%), and CFTR (23%). Results were compared with those from whole exome sequencing of a similar set of 35 HGSC patients. Somatic variants in TP53 were also validated using GENIE data of 1287 HGSC samples. Our approach showed increased prevalence of high impact somatic and germline mutations, especially those affecting splice sites of TP53, compared to validation datasets. Furthermore, nonsense TP53 somatic mutations were negatively associated with patient survival. Elevated TP53 transcript levels were associated with platinum resistance and presence of TP53 missense mutations, while decreased TP53 levels were found in tumors carrying mutations with predicted high impact, which was confirmed in The Cancer Genome Atlas data (n = 260). Targeted DNA sequencing of TP53 combined with transcript quantification may contribute to the concept of precision oncology of HGSC. Future studies should explore targeting the p53 pathway based on specific mutation types and co-analyze the expression and mutational profiles of other key cancer genes.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory vaječníků $x genetika $x farmakoterapie $x patologie $7 D010051
650    12
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    12
$a chemorezistence $x genetika $7 D019008
650    12
$a serózní cystadenokarcinom $x genetika $x farmakoterapie $x patologie $7 D018284
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    _2
$a zárodečné mutace $7 D018095
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a sekvenování exomu $x metody $7 D000073359
650    _2
$a platina $x terapeutické užití $x farmakologie $7 D010984
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hlaváč, Viktor $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000306950552 $7 xx0270481
700    1_
$a Šeborová, Karolína $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000289252321
700    1_
$a Šůsová, Simona $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Tesařová, Tereza $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000210357375
700    1_
$a Rob, Lukáš $u Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Hruda, Martin $u Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Bouda, Jiří $u Department of Gynecology and Obstetrics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Bartáková, Alena $u Department of Gynecology and Obstetrics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Mrhalová, Marcela $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kopečková, Kateřina $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Al Obeed Allah, Mohammad $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Špaček, Jiří $u University Hospital Hradec Králové, Hradec Kralove, Czech Republic
700    1_
$a Sedláková, Iva $u University Hospital Hradec Králové, Hradec Kralove, Czech Republic
700    1_
$a Souček, Pavel $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000242946799 $7 xx0060511
700    1_
$a Václavíková, Radka $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0009000047293371
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 155, č. 1 (2024), s. 104-116
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38447012 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133415 $b ABA008
999    __
$a ok $b bmc $g 2143309 $s 1225278
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 155 $c 1 $d 104-116 $e 20240306 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
GRA    __
$a NU20-09-00174 $p Czech Health Research Council
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace